T he central nervous system (CNS) is strongly implicated in the pathogenesis of renovascular hypertension (RVH), a disease that is characterized by renal artery stenosis most commonly caused by atherosclerosis. 1 The stenotic kidney responds to reduction in perfusion pressure by secreting renin from juxtaglomerular cells, which leads to an initial increase in circulating levels of angiotensin II (Ang II) and an elevation in blood pressure. 2 However, as demonstrated in experimental animal models of RVH such as 2-kidney, one-clip (2K1C) Goldblatt hypertension, initial elevations in circulating Ang II levels subside, and renal homeostasis returns to normal in later phases. Nevertheless, pathological hypertension is maintained. 3, 4 Although several potential mechanisms may contribute (eg, altered renal reflexes), several laboratories, including ours, have identified the brain renin-angiotensin system (ie, Ang II that is produced and acts specifically in the brain) as a critical mediator of chronic hypertension in this model. [3] [4] [5] Abundant evidence now suggests that a key mechanism in the neurogenic control of blood pressure is the production of nicotinamide adenine dinucleotide phosphate-oxidase (Nox)-derived reactive oxygen species (ROS) such as superoxide (O 2 Ϫ⅐ ) in the CNS. 6 -8 Work from our laboratory and others has shown that Ang II, administered either directly into the CNS or systemically in subpressor doses over weeks (ie, "slow-pressor"), causes hypertension along with Ang II receptor 1-and Nox-mediated ROS production in central cardioregulatory nuclei. 9 -11 Both the ROS production and hypertension can be prevented by genetic or chemical ROS scavengers or Nox inhibitors administered in the brain, 9, 12, 13 suggesting a causative role of brain ROS signaling in Ang II-dependent hypertension.
The paraventricular nucleus (PVN) of the hypothalamus is a key site of autonomic and neurohumoral regulation, and both Ang II and ROS are known to be potent mediators of these processes. Either local production of Ang II in the PVN or activation of angiotensinergic signaling in the PVN through blood-borne Ang II binding Ang II receptor type 1 (AT 1 ) in upstream circumventricular organs can cause alterations in sympathetic reflexes/activity, baroreflex sensitivity, or secretion of arginine vasopressin. 14 Recently, oxidant signaling has been shown to be important in at least some of these Ang II-mediated effects in the PVN. For example, the cardiac sympathetic afferent reflex involves Ang II-mediated ROS formation in the PVN. 15 In addition, both acute central 16 and chronic systemic pressor effects of Ang II 17 are linked to Nox-dependent ROS formation in the PVN. Recent work from our laboratory shows that Nox4-mediated O 2 Ϫ⅐ production in the PVN mediates sympathoexcitation and cardiac dysfunction in a mouse model of heart failure. 18 Blood-borne Ang II signaling through the circumventricular subfornical organ is a likely upstream mediator of this response. 19, 20 In 2K1C RVH, aberrant Ang II signaling in the PVN has been implicated in the hypertension, increased sympathetic discharge, and attenuation of baroreflex function observed in this model. 4, 21 However, the underlying signaling mechanisms are largely unknown.
The molecular pathways by which ROS mediate long-term changes in central neural circuits involved in diseases such as hypertension and heart failure are yet to be elucidated. Emerging evidence suggests that redox-regulated transcription factor (TF) activation and ensuing alterations in gene profiles in these circuits may be involved. 17, 22 The redoxregulated activator protein 1 (AP-1) transcription complex may have particular relevance in this regard because 2 of its members, c-Fos and c-Jun, have been used extensively as marker proteins for activated CNS neurons in models of chronic cardiovascular disease. 19, 23 Further, abundant evidence shows that Ang II increases AP-1 family member levels and activity in the PVN and other central cardiovascular regions in vivo. 17,24 -26 Considering the importance of ROS signaling in the PVN in several neurocardiovascular diseases, we hypothesized that oxidant signaling in the PVN plays an important role in the hypertension evoked by renal artery stenosis. Further, given recent evidence that redox-regulated TFs mediate Ang IIinduced changes in CNS circuits involved in chronic diseases such as hypertension, we hypothesized that AP-1 activation in the PVN would be associated with redox signaling and elevations in blood pressure induced by renal artery clipping. We used the 2K1C model of RVH in mice and modulated O 2 Ϫ⅐ levels selectively in the PVN by targeted adenoviral (Ad) delivery of cytoplasmic superoxide dismutase (AdCuZnSOD) to this brain region. In addition, we used an Ad encoding a luciferase reporter downstream of AP-1 response elements (AdAP-1Luc) in conjunction with bioluminescence imaging (BLI) 22 to longitudinally track AP-1 activity in the PVN in vivo during the development and progression of RVH. Our data show that hypertension in this model is associated with increased O 2 Ϫ⅐ production and AP-1 activation in the PVN. PVN-targeted overexpression of CuZnSOD abolished these increases in O 2 Ϫ⅐ and AP-1 activation. Further, expression of either CuZnSOD or a dominant-negative inhibitor of AP-1 activity in the PVN protected against RVH in this model.
Methods
An expanded Methods section can be found in an online supplement available at http://hypertension.ahajournals.org.
Animals
Adult C57BL/6 mice (8 to 12 weeks of age) were used. All procedures were approved by the institutional animal care and use committee at Cornell University.
Adenoviral Vectors
Ad vectors encoding for human cytoplasmic superoxide dismutase (AdCuZnSOD) and bacterial ␤-galactosidase (AdLacZ) were obtained from the University of Iowa Gene Transfer Vector Core. Ad vectors encoding an AP-1-responsive luciferase reporter construct (AdAP-1Luc) and a dominant-negative c-Jun NH 2 -terminal kinase 1 JNK1 (Ad-dnJNK1) were kindly provided by Dr John F. Engelhardt (University of Iowa, Iowa City, IA).
Radiotelemeter Implantation and Gene Transfer to the PVN
Mice were instrumented with radiotelemeters as described, 4, 9 followed by stereotaxic bilateral PVN microinjections of AdLacZ, AdCuZnSOD, or Ad-dnJNK1. For in vivo BLI studies, nontelemetered mice underwent bilateral PVN microinjection of a 1:1 mixture of AdAP-1Luc/AdLacZ or AdAP-1Luc/AdCuZnSOD as described. 22
2K1C RVH Model
One week after telemeter implantation and PVN microinjection, mice were anesthetized with isofluorane. The right renal artery was exposed through a midline abdominal incision, and a silver clip was placed over the vessel as described. 4 A sham procedure served as control.
In Vivo BLI
To longitudinally track AP-1 activation in the PVN in vivo, AdAP1Luc was used in conjunction with in vivo BLI as described. 22 Animals underwent sham or 2K1C surgery 2 weeks after AdAP1Luc gene transfer, after which daily bioluminescence images were acquired with the IVIS200 daily until 28 days after surgery. At the end of the study, systemic endotoxin-induced activation of AP-1 was assessed by injection of lipopolysaccharide. 22 
ROS Measurements in Brain Sections
Dihydroethidium (DHE) staining was performed as described. 9, 18 On days 5 and 14 after surgery, brains were removed, cryosectioned, and treated with DHE. DHE fluorescence was visualized by confocal microscopy and quantified using ImageJ as described. 9 
CuZnSOD and Luciferase Immunohistochemistry
Mice were perfused, and brains were removed and cryosectioned. Free-floating sections were processed for immunofluorescence with antibodies to luciferase, CuZnSOD, neuronal nuclei, or glial fibrillary acidic protein as described. 9, 18, 19 Sections were analyzed by confocal microscopy.
Body and Kidney Weights
Mice were weighed and euthanized at the end of the telemetry experiments (day 28), and kidneys were removed and weighed to confirm atrophy of the clipped kidney and hypertrophy of the contralateral unclipped kidney.
Statistical Analyses
Results are expressed as meanϮSEM. All data were analyzed by 1-way analysis of variance (ANOVA) and Newman-Keuls post tests, except changes in mean arterial pressure (MAP) and heart rate (HR) from baseline, which were assessed by repeated-measures ANOVA with the Tukey multiple comparison post test. Significance was defined as PϽ0.05.
Results

PVN-Targeted Scavenging of Ctyoplasmic O 2
؊⅐
Protects Against 2K1C Hypertension
Changes in MAP and HR induced by unilateral renal artery clipping (or sham surgery) are presented in Figure 1 . In mice treated with the control AdLacZ vector in the PVN, renal artery occlusion resulted in a gradual rise in MAP that became significantly elevated above baseline and sham controls by day 5 postclip, and reached maximum by 1 week. Blood pressure in this group remained at this level throughout the rest of the experimental period (3 weeks). In AdCuZnSOD-treated mice that underwent renal artery clipping, MAP was elevated above sham controls for 1 day postclip (day 2). However, on all days thereafter, MAP in this group returned to sham levels and was significantly attenuated compared with control virus-treated 2K1C mice (days 6 to 28; 2K1CϩAdLacZ versus 2K1Cϩ AdCuZnSOD; PϽ0.05). Blood pressure was not significantly altered in sham mice treated with AdLacZ at any time during the study, nor was HR different between the 3 groups throughout the experiment. Baseline preclip MAP (ShamϩAdlacZϭ101Ϯ5, nϭ6; 2K1CϩAdlacZϭ109Ϯ1, nϭ4; 2K1CϩAdCuZnSODϭ 105Ϯ6, nϭ6; PϾ0.05) and HR (ShamϩAdlacZϭ563Ϯ24, nϭ6; 2K1CϩAdlacZϭ582Ϯ28, nϭ4; 2K1CϩAdCuZnSODϭ 554Ϯ17, nϭ6; PϾ0.05) were also not different between the treatment groups, suggesting that O 2 Ϫ⅐ scavenging in the PVN does not alter basal cardiovascular function. Together, these results suggest that O 2 Ϫ⅐ signaling in the PVN is critical in mediating 2K1C hypertension, both during the early development and chronic phases.
Renal Artery Clipping Induces CuZnSOD-Sensitive AP-1 Transcriptional Activity in the PVN
Given that AP-1 activation is redox sensitive 27 and may be important in mediating long-term changes in CNS cardiovascular networks, 17,24 -26 we hypothesized that RVH involves ROSdependent AP-1 activation in the PVN. To test this, the AP-1 reporter virus Ad-AP-1Luc was microinjected selectively into PVN. This was then coupled with in vivo BLI for noninvasive real-time monitoring of AP-1 activation after renal artery occlusion. Figure 2 shows representative BLI images ( Figure 2A ) and a summary of AP-1-dependent photon flux over time (grouped in 2-day bins; Figure 2B ). Baseline photon flux, averaged over 4 consecutive days before 2K1C or sham surgery, was at low levels and not different between the groups. This level of background flux is consistent with what we have shown previously using this technology. 22 Starting 3 to 4 days after clipping, the AP-1-dependent luminescent signal began to rise significantly compared with sham animals (Figure 2A and 2B; 2K1CϩAdLacZ versus ShamϩAdLacZ; PϽ0.05). By 5 to 6 days after surgery, AP-1 activation in the PVN of the 2K1C group surged to Ϸ5-fold greater levels compared with sham controls (Figure 2A and 2B) . AP-1-dependent photon flux in clipped mice remained significantly elevated compared with sham animals until 13 to 14 days postclip (2K1CϩLacZ versus ShamϩAdLacZ; PϽ0.05), albeit at lower levels compared with the surge at 5 to 6 days ( Figure 2B ). To examine the role of redox signaling in this 2K1C-induced AP-1 activation, photon flux was investigated in mice that had undergone PVN-selective injections of Ad-AP-1ϩAdCuZnSOD. In these mice, the 2K1C-induced increases in AP-1 activity observed in AdLacZ-treated mice on days 3 through 14 were significantly attenuated ( Figure  2B ; 2K1CϩAdCuZnSOD versus 2K1CϩAdLacZ; PϽ0.05). After the 2-week time point and for the duration of the study, AP-1 activity was not significantly different between the groups. In addition, photon flux was not altered at any time point in sham animals compared with baseline. On the final day of the study (day 28; Ϸ6 weeks after initial gene transfer), we verified that AP-1Luc had retained the functional capacity for activation in vivo using systemic challenge with lipopolysaccharide (4 g/g IP). AP-1 is known to be activated in the PVN on systemic lipopolysaccharide administration. 22 Lipopolysaccharide induced profound increases in AP-1-dependent luminescence in both sham and 2K1C groups, confirming functional expression of AP-1Luc until the end of the study ( Figure 2B , far right panel).
It should be noted that in addition to temporal resolution, spatial localization of AP-1 activation in PVN is verified by virtue of the fact that the Ad-AP-1 reporter was injected site selectively. 22 This is an important point because the scattering of visible light through tissue prevents the surface-weighted signal itself from strictly informing of the 3D position of the luminescence source. 22 However, because the luciferase reporter was delivered selectively to PVN, we have independent confirmation of spatial localization of AP-1 activation. 
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To provide further evidence of this, immunohistochemical staining of luciferase was performed at day 28. As seen in Figure 2C , luciferase was expressed at high levels bilaterally in the PVN. Together, these results suggest that renal artery clipping induces O 2 Ϫ⅐ -dependent AP-1 transcriptional activity in the PVN during the initiation and early phase of hypertension in this model.
AdCuZnSOD Prevents 2K1C-Induced ROS Formation in the PVN
Data in Figure 1 suggest that 2K1C-induced increases in O 2 Ϫ⅐ levels in the PVN are associated with increased MAP in this model. BLI results in Figure 2 show that AP-1 activation in the PVN in response to renal artery clipping is CuZnSOD sensitive and with a time course that parallels the rise in MAP. These results implicate 2K1C-induced increases in O 2 Ϫ⅐ in the PVN, and here we sought to confirm this directly by measuring ROS levels in this brain region at 5 and 14 days postclip using DHE confocal microscopy. As shown in representative images of DHE fluorescence (day 14; Figure  3A ) and summary data at both time points (Figure 3B ), renal artery clipping increased ROS levels in the PVN of mice treated with the control virus. This occurred during the early-phase postclip, coinciding with the start of the rise in MAP and the peak AP-1 activation response (day 5). Elevated ROS levels in the PVN were maintained at day 14, a time when MAP was maximum in the AdLacZ group but back to baseline in the AdCuZnSOD-treated animals ( Figure 1 ). 2K1C-induced increases in PVN ROS levels were significantly blunted at both time points by AdCuZnSOD ( Figure  3A and 3B), implicating O 2 Ϫ⅐ as the radical species involved in both the initiation and maintenance of hypertension in this model.
Localization of CuZnSOD in PVN
We have shown previously that AdCuZnSOD induces robust, localized, and stable CuZnSOD expression and SOD activity in cardiovascular nuclei of the CNS. 9 
PVN-Targeted Expression of dnJNK1 Ameliorates 2K1C Hypertension
Data presented in Figures 1 and 2 demonstrate that 2K1C-induced hypertension is associated with AP-1 activation in the PVN. To determine whether there is a causal link between these 2 responses, we injected an adenovirus encoding a dominant-negative inhibitor of AP-1 transcriptional activation (Ad-dnJNK1) into the PVN before renal artery clipping. Summary data in Figure 5 demonstrate that PVN-targeted dnJNK1 expression prevented the 2K1C-induced rise in MAP in both the early and chronic phases. Similar to Figure 1 
Renal Atrophy Induced by Renal Artery Clipping
Kidneys were weighed at the end of the 4-week period in a subset of sham, 2K1CϩAdLacZ, 2K1CϩAdCuZnSOD, and 2K1CϩAd-dnJNK1 animals to confirm atrophy of the clipped kidney and hypertrophy of the contralateral unclipped kidney. 30 As shown in the 32, 33 The initial rise in MAP coincided with increases in ROS production and a dramatic surge in AP-1 transactivation in the PVN. Each of these PVN responses was sustained through 2 weeks postclip, coinciding with the chronic phase of hypertension. AdCuZnSOD targeted to the PVN abolished both the ROS and AP-1 responses. This was associated with an attenuation of both the early and chronic phases of hypertension. Similarly, dominant-negative inhibition of AP-1 transcription in PVN with Ad-dnJNK1 prevented both phases of 2K1C-evoked hypertension. These results implicate O 2 Ϫ⅐ signaling and AP-1 transcriptional activity in the PVN as key mediators of RVH.
The upstream signaling events that lead to increased O 2 Ϫ⅐ production in the PVN after renal artery stenosis remain unclear, although locally generated Ang II is a leading candidate given its well-established role in several neurocardiovascular diseases including RVH, 34 as well as previous data showing that Ang II is elevated in the hypothalamus during both the early and chronic phases of 2K1C hypertension, 4 with AT 1 receptor mRNA levels also being upregulated in the PVN. 21 Given that a major mechanism through which Ang II exerts its powerful effects on central control of blood pressure is redox signaling, 6 we first tested the hypothesis that 2K1C hypertension involves oxidant stress in the PVN. Indeed, renal artery clipping induced CuZnSOD-sensitive ROS increases in the PVN during the initial rise in MAP (day 5), suggesting that O 2 Ϫ⅐ signaling in this brain region may be involved in the development of RVH. To test this directly, PVN-targeted AdCuZnSOD treatment was used before placement of the clip. This led to attenuation of 2K1C-induced hypertension during the early phase, suggesting that the development of hypertension in this model does involve cytoplasmic O 2 Ϫ⅐ signaling in the PVN. Because AdCuZn-SOD targeted to this brain region also ameliorated hypertension during the chronic phase, in addition to normalizing ROS levels in the PVN at 2 weeks postclip, these data suggest that O 2 Ϫ⅐ signaling in the PVN is also critical in the maintenance phase of RVH. Importantly, this occurred despite sustained 2K1C-induced renal atrophy. These results are consistent with those of Oliveira-Sales et al, whose findings support a role for ROS in the PVN in RVH; however, their studies used acute microinjection of Tempol unilaterally into PVN of anesthetized rats and showed that established hypertension (after 6 weeks) could be transiently reversed by this treatment. 21 Our experimental design involving long-term gene transfer of CuZnSOD to PVN before renal artery clipping leads us to conclude that cytoplasmic O 2 Ϫ⅐ signaling in the PVN plays a causal role in RVH. Studies using PVN-specific ablation of AT 1 receptors through Cre-loxP technology 35 will be important to verify whether Ang II signaling in the PVN is indeed functionally linked to 2K1C-induced oxidant stress and RVH. In addition, because Ad-mediated CuZnSOD transduction occurred in both neurons and glia of the PVN, additional studies will be required to determine the relative role of O 2 Ϫ⅐ signaling in these 2 cell types. Additional future studies should aim to determine the enzymatic source of 2K1C-induced ROS formation in the PVN. It is certainly well established that Nox is a primary source of ROS, mediating many cardiovascular responses, including central neural control of blood pressure and related parameters. 6,9 -12,36 Recently, Nox-derived ROS have been implicated in RVH. Several studies have shown that systemic treatment with the antioxidants Tempol or apocynin relieve several peripheral pathologies associated with RVH in rats, including endothelial dysfunction, impairment in renal hemodynamics, and increased renal sympathetic nerve activity. 31, 37, 38 In addition, Wang et al demonstrated that Ang II-stimulated Nox contributes to the development of 2K1C hypertension and cardiac remodeling in rats. 39 Interestingly, Nox has also been implicated recently in the CNS component of RVH. Oliveria-Sales et al showed that both Nox2 and p47phox were markedly upregulated in PVN of rats with 2K1C hypertension. 21 Using viruses encoding small interfering RNAs targeted against Nox1, Nox2, or Nox4, 12, 18, 40 it should be possible to dissect the relative functional role of each of these homologues in ROS formation in the PVN and 2K1C RVH.
The downstream molecular mechanisms by which increased O 2 Ϫ⅐ in the PVN leads to chronic hypertension in this model was the next focus of this study. Effectors of O 2 Ϫ⅐ in CNS cardioregulatory nuclei have been the subject of several recent studies, with evidence that kinase cascades, calcium transients, and delayed rectifier potassium channels may be involved. 6, 11, [41] [42] [43] However, many of these studies focused on the effects of relatively short-term stimulation of ROS production. Because O 2 Ϫ⅐ signaling in the context of our study was involved in chronic regulation of blood pressure, we focused on ROS-sensitive TFs because of their well-known role in long-term modulation of a wide variety of CNS parameters 44 and an emerging role in CNS cardiovascular circuits. For example, Liu et al have shown that Ang II induces AT 1 receptor upregulation in the rostral ventrolateral medulla by an increase in ROS-dependent activation of AP-1 in brains of chronic heart failure rabbits. 26 In addition, a recent report by Kang et al shows that chronic systemic infusion of Ang II in rats causes ROS-dependent activation of nuclear factor B in the PVN. 17 Both of these studies used gel mobility shift assays to examine TF activation in brain nuclei at a few select time points during these chronic conditions. However, because we were interested in the full time course of TF activation in the PVN during the development and progression of RVH, we turned to in vivo BLI technology for longitudinal real-time monitoring of AP-1 activation. Our results demonstrate that renal artery clipping caused a small but significant increase in AP-1 transcriptional activation in the PVN as early as 3 to 4 days postclip. This transitioned to a marked surge in activity over the following 2 days, followed by sustained elevations compared with shams for another week, albeit at lower levels compared with the early surge. AP-1 activity in the PVN then returned to basal levels for the remaining 2 weeks of the experiment. The sensitivity of these increases in AP-1-dependent photon flux to AdCuZnSOD suggest that activity of this TF in PVN is O 2 Ϫ⅐ regulated. It is interesting to speculate about the time course of AP-1 activation in the context of the different phases of 2K1C-induced RVH in this study. Genes encoding Fos and Jun family proteins, which form the AP-1 complex that binds AP-1 sites in gene promoters, are termed immediate early genes because of their classic quick and transient induction (ie, hours) in response to a variety of stimuli. 45 However, more recently, some family members such as isoforms of FosB, which are important in CNS adaptation, were shown to be induced only by more chronic stimuli and persist for longer periods of time (ie, days to weeks to months). 46 Although our strategy for measuring AP-1 activation in the current study does not allow for resolution of the various family members involved, we speculate that the early robust increases in AP-1 transcriptional activity leads to changes in PVN neural networks that play a key role in initiating the long-term changes in blood pressure in this model. This was supported by the finding that AdCuZnSOD injection into PVN blocked both the AP-1 transactivation and chronic hypertension in this model. Further, because dominantnegative inhibition of AP-1 in the PVN prevented 2K1C-evoked rises in MAP, this suggests that its transcriptional activity is functionally linked to hypertension in this model.
The physiological effectors in the PVN that lead to 2K1C hypertension have been the subject of many investigations. On the one hand, increased arginine vasopressin release has been implicated in this model over the years, 47, 48 and there are strong links between Ang II, ROS, and AP-1, with increased activation of vasopressinergic neurons in the PVN. 49 -51 However, there are other reports that arginine vasopressin is not involved in 2K1C hypertension. 52 More recently, it is thought that PVN involvement in RVH is through activation of rostral ventrolateral medulla-projecting parvocellular neurons in this region, leading to increased sympathoexcitation. 21 Interestingly, ROS are now also implicated in this pathway. 21 Further studies will be required to determine the physiological effectors that are downstream of ROS and AP-1 activation in PVN during 2K1C hypertension.
Perspectives
Our data suggest that 2K1C-induced RVH in mice is mediated by oxidative stress-induced AP-1 activation in the PVN. This is supported by the following observations: (1) the development of 2K1C hypertension is associated with a 
